Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03525873 · ClinicalTrials.gov registry record · Phase 3
A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy
A Phase 3 study of Advanced Malignant Neoplasm and Metastatic Malignant Neoplasm, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 3
- Development phase
- 212
- Enrollment target
- 1
- Study location
NCT03525873 is a Phase 3 study of Advanced Malignant Neoplasm and Metastatic Malignant Neoplasm that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 212 participants, above the 163-participant average among 16 other Advanced Malignant Neoplasm trials with a reported enrollment target (30% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03525873, a Phase 3 study of Advanced Malignant Neoplasm and Metastatic Malignant Neoplasm, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 212 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase III trial studies how well methylphenidate and physical activity works in reducing cancer-related fatigue in patients who are receiving anti-PD1 immunotherapy for cancer that has spread to other places in the body. Central nervous systems stimulants, such as methylphenidate, may help to improve cognitive function. Physical activity uses techniques, such as aerobic and resistance exercises, which may help to improve quality of life. Giving methylphenidate and physical activity may help in reducing cancer-related fatigue in patients with metastatic cancer who receive anti-PD1 immunotherapy.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- DRUG Methylphenidate
- OTHER Physical Activity
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2018-08-02 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03525873
The ClinicalTrials.gov registry entry for NCT03525873 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 163-participant average among 16 other Advanced Malignant Neoplasm trials with a reported enrollment target (30% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Advanced Malignant Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03525873 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03525873 about?
NCT03525873 is a clinical study titled "A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy". This phase III trial studies how well methylphenidate and physical activity works in reducing cancer-related fatigue in patients who are receiving anti-PD1 immunotherapy for cancer that has spread to other places in the body. Central nervous systems stimulants, such as methylphenidate, may help to i...
What is the current status of trial NCT03525873?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 212 participants. The study started on 2018-08-02. Estimated completion is 2026-12-31.
What conditions does trial NCT03525873 study?
This clinical trial studies the following conditions: Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm.
What interventions are being tested in trial NCT03525873?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Methylphenidate (DRUG), Physical Activity (OTHER).
Who is sponsoring clinical trial NCT03525873?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03525873 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RECRUITING · Phase 1
-
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
RECRUITING · Phase 1
-
Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center
ACTIVE NOT RECRUITING · NA
-
Cordotomy in Reducing Pain in Patients With Advanced Cancer
ACTIVE NOT RECRUITING · NA
-
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.